Loading…
← CockpitCompetitor Analysis › 0411.HK Lam Soon (Hong Kong) LimitedOpen in the cockpit ↗

Lam Soon (Hong Kong) Limited0411.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Consumer Staples›Food: Specialty/Candy
Momentum neutral 52
Mkt cap
$330M
US dollars, full cap
Free float
26%
of shares outstanding
$/day
$16,911
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+12.6 pp
WACC 5.3%
Hurdle
n/a
no reverse DCF
Close · HKDHK$11.00
1Dn/a
1W0.0%
1M-8.2%
3M-14.7%
6M-3.5%
YTD-3.1%
1Y+30.9%
ATR %2.8%
52w lowhigh35.3% off high

What Lam Soon (Hong Kong) does

Employees: 1,480

Lam Soon (Hong Kong) at a glance

Size Lam Soon (Hong Kong) (0411.HK) is a Hong Kong Consumer Staples company (Food: Specialty/Candy) with a market value of $330M, the 866th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$11.00 on 6 Nov 2026.

Performance Over six months the shares fell 3.5%, against -10.1% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue grew 4.8% over the last twelve months (peer median +9.0%); the operating margin is 5.8% (peer median 5.8%).

Valuation It trades at 0.1× enterprise value to sales against a peer median of 1.9× (cheapest of 21).

Capital Return on invested capital runs 12.6 points above its cost of capital (5.3% WACC).

Relative performance

9010011012011 May 202611 Aug 20266 Nov 20260411.HK 104Peer median 89
Six months, rebased to 100: Lam Soon (Hong Kong) against the median of its 20 peers (local-currency closes).

Lam Soon (Hong Kong) financials

Reported figures in HKD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueHK$5.06BHK$5.06BHK$4.83BHK$4.84BHK$5.12B
Revenue growth—+5%0%-5%—
Gross profitHK$1.16BHK$1.16BHK$1.12BHK$1.01BHK$875M
EBITDAHK$367MHK$367MHK$365MHK$260MHK$123M
Net incomeHK$293MHK$293MHK$303MHK$201MHK$85.3M
Free cash flown/aHK$213MHK$213MHK$247MHK$144M
Capital expendituren/aHK$130MHK$59.4MHK$40.4MHK$49.4M
Total debtn/aHK$17.3MHK$12.3MHK$3.95MHK$4.18M

Quarterly statements and history in the cockpit →

Lam Soon (Hong Kong) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%-40%-20%0%P34ADVENZYMESGOPAL22260026612207BON122640ADFFOODSOFRM2211000972603755Q010027723012202723YASHO3006730411.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Lam Soon (Hong Kong) is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%0×2×4×6×P34ADVENZYMESGOPAL22260026612207BON122640ADFFOODSOFRM221100097260375500277230122027238079YASHO3006730411.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lam Soon (Hong Kong) is the large dot.

Lam Soon (Hong Kong) competitors and peer comparison

How Lam Soon (Hong Kong) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lam Soon (Hong Kong) against its 20 peers (data as of 6 Nov 2026)
Measure0411.HKPeer medianRank in peer set
1-month return-8.2%-3.8%10th lowest of 21
6-month return-3.5%-10.1%8th highest of 21
Distance from 52-week high-35.3%-30.8%7th lowest of 21
Revenue growth (TTM)+4.8%+9.0%9th lowest of 21
Operating margin5.8%5.8%11th highest of 21
EV / Sales0.1×1.9×cheapest of 21
ROIC minus cost of capital+12.6 pp-0.7 pphighest of 21
EV / EBITDA1.5×10.2×cheapest of 15
Net debt / EBITDA-5.6×0.9×least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lam Soon (Hong Kong) 0411.HKHong Kong$330M-4%+5%6%0.1×n/an/a
Delfi P34.SISingapore$328M-34%-2%7%0.5×-12.8%+4.2%
Advanced Enzyme Technologies ADVENZYMES.NSIndia$333M-22%+10%25%3.3×19.1%+8.3%
Gopal Snacks GOPAL.NSIndia$324M-26%+20%5%1.9×n/an/a
KOIKE-YA 2226.TJapan$321M+2%+3%7%0.9×n/an/a
Chen Ke Ming Food Manufacturing 002661.SZChina$342M-22%0%-2%1.1×-3.0%+1.9%
Meito 2207.TJapan$342M+3%+3%3%2.3×n/an/a
Bonduelle SCA BON.PAFrance$294M0%-1%4%0.4×-3.4%+0.2%
YEST 122640.KSSouth Korea$283M-32%+10%6%4.0×n/an/a
ADF Foods ADFFOODS.NSIndia$280M-10%+19%16%3.7×n/an/a
Once Upon a Farm, PBC OFRMUnited States$389M-43%+43%-6%1.0×n/an/a
Fujiya 2211.TJapan$393M-1%+6%1%0.6×n/an/a
Chalkis Health Industry 000972.SZChina$397M-9%+17%-52%6.9×-6.8%+89.3%
Qingdao Richen Food 603755.SSChina$407M-5%+11%17%6.3×20.1%+12.3%
QAF Q01.SISingapore$408M-10%0%6%0.5×-10.6%+2.4%
Tianshui Zhongxing Bio-Technology 002772.SZChina$410M-54%+12%14%1.9×n/an/a
Kunshan Asia Aroma 301220.SZChina$413M-35%+13%6%2.6×10.8%+12.4%
Gourmet Master 2723.TWTaiwan$431M+19%-11%5%0.8×0.9%-1.7%
Shoei Foods 8079.TJapan$435M+1%+8%4%0.6×n/an/a
Yasho Industries YASHO.NSIndia$441M+122%+35%14%4.4×33.4%+17.7%
Petpal Pet Nutrition Technology 300673.SZChina$444M-26%+2%6%2.1×7.5%+1.6%

Questions

Which companies are Lam Soon (Hong Kong)'s closest peers?
The cockpit's peer set: Delfi (P34.SI), Advanced Enzyme Technologies (ADVENZYMES.NS), Gopal Snacks (GOPAL.NS), KOIKE-YA (2226.T), Chen Ke Ming Food Manufacturing (002661.SZ), Meito (2207.T), Bonduelle SCA (BON.PA), YEST (122640.KS).
Is Lam Soon (Hong Kong) expensive compared with its peers?
On ev / sales it trades at 0.1× against a peer median of 1.9×, cheapest of 21 in its peer set.
How has Lam Soon (Hong Kong) stock performed?
Over six months to 6 Nov 2026 the shares returned -3.5% against -10.1% for the median peer; over one year +30.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.